脱氧核糖核酸倍体和S期分数对宫颈癌患者而言并非显著的预后因素。

Deoxyribonucleic acid ploidy and S-phase fraction are not significant prognostic factors for patients with cervical cancer.

作者信息

Jelen I, Valente P T, Gautreaux L, Clark G M

机构信息

Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio.

出版信息

Am J Obstet Gynecol. 1994 Dec;171(6):1511-6; discussion 1516-8. doi: 10.1016/0002-9378(94)90394-8.

DOI:10.1016/0002-9378(94)90394-8

PMID:7802060

Abstract

OBJECTIVE

Our purpose was to determine the usefulness of deoxyribonucleic acid ploidy and S-phase fraction as prognostic factors in patients with cervical cancer.

STUDY DESIGN

Paraffin-embedded tumor specimens were obtained from 123 patients with cervical cancer (mean age 51 years, range 21 to 87 years). The mean follow-up period was 6.4 years. Deoxyribonucleic acid ploidy and S-phase fraction were determined by flow cytometry.

RESULTS

A total of 119 patients were evaluable for deoxyribonucleic acid ploidy and 92 were evaluable for S-phase fraction. The overall rate of deoxyribonucleic acid aneuploidy was 60%, and the median S-phase fraction was 12.5%. Neither factor was significantly related to stage of disease. In univariate survival analyses patients with deoxyribonucleic acid aneuploid tumors had slightly better early survival than did patients with deoxyribonucleic acid diploid tumors (median survivals 2.7 and 1.4 years, respectively, p = 0.08 [Wilcoxon]), but the overall survival was not significantly different, p = 0.37 (log-rank). In multivariate analyses deoxyribonucleic acid ploidy was not a significant predictor of survival. S-phase fraction was not statistically significant in either analysis.

CONCLUSION

Deoxyribonucleic acid ploidy and S-phase fraction are not useful prognostic factors for patients with cervical cancer.

摘要

目的

我们的目的是确定脱氧核糖核酸倍体和S期分数作为宫颈癌患者预后因素的有用性。

研究设计

从123例宫颈癌患者（平均年龄51岁，范围21至87岁）获取石蜡包埋的肿瘤标本。平均随访期为6.4年。通过流式细胞术确定脱氧核糖核酸倍体和S期分数。

结果

共有119例患者可评估脱氧核糖核酸倍体，92例可评估S期分数。脱氧核糖核酸非整倍体的总体发生率为60%，S期分数中位数为12.5%。这两个因素均与疾病分期无显著相关性。在单变量生存分析中，脱氧核糖核酸非整倍体肿瘤患者的早期生存率略高于脱氧核糖核酸二倍体肿瘤患者（中位生存期分别为2.7年和1.4年，p = 0.08 [威尔科克森检验]），但总体生存率无显著差异，p = 0.37（对数秩检验）。在多变量分析中，脱氧核糖核酸倍体不是生存的显著预测因素。在任何一项分析中，S期分数均无统计学意义。